Vimarsana
Biggest News Aggregation in the World

Page 24 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

AstraZeneca reinforces leadership in breast cancer at SABCS 2021 with new data underscoring ambition to redefine cancer care - Vimarsana News

AstraZeneca reinforces leadership in breast cancer at SABCS 2021 with new data underscoring ambition to redefine cancer care

AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio

AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021 - Vimarsana News

AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021

AstraZeneca will present new data underscoring its commitment to transforming haematologic cancer care at the 63rd American Society of Hematology

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Imfinzi approved in China for extensive-stage SCLC - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Imfinzi approved in China for extensive-stage SCLC

  of extensive-stage small cell lung cancer   Only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies   AstraZeneca's Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).   The approval by China's National Medical Products Administration was ba...

AstraZeneca's Calquence head-to-head results versus ibrutinib - DirectorsTalk Interviews - Vimarsana News

AstraZeneca's Calquence head-to-head results versus ibrutinib - DirectorsTalk Interviews

AstraZeneca's Calquence head-to-head results versus ibrutinib

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence head-to-head results versus ibrutinib - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence head-to-head results versus ibrutinib

Investegate announcements from AstraZeneca PLC, Calquence head-to-head results versus ibrutinib